

Name of journal: World Journal of Meta-Analysis

ESPS Manuscript NO: 20949

Manuscript Type: META-ANALYSIS

Risk of pancreatic adverse events ⁶ associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials

Hasan M Shihab, Tokunbo Akande, Kacie Armstrong, Sonal Singh, Yoon Kong Loke

Abstract

Match Overview

1	CrossCheck 101 words Vaniyapong, Tanat, Wilaiwan Chongruksut, Kittipan Rerkasem, and Kittipan Rerkasem. "Local versus general e...	2%
2	Internet 73 words crawled on 19-Jul-2015 archinte.jamanetwork.com	2%
3	CrossCheck 35 words Alves, Carlos, Francisco Batel-Marques, and Ana F. Mac edo. "A meta-analysis of serious adverse events repor ...	1%
4	Internet 32 words crawled on 21-May-2015 www.ncbi.nlm.nih.gov	1%
5	Internet 27 words crawled on 05-Aug-2010 www.mybiosource.com	1%
6	Internet 25 words crawled on 29-May-2015 www.bmj.com	1%

Do GLP-1–Based Therapies Increase Cancer Risk? - Diabetes Care

care.diabetesjournals.org/content/36/Supplement_2/S245.long

Furthermore, in rodents like mice and rats, stimulating the **GLP-1 receptor** raises ... of acute **pancreatitis associated** with the **use** of exenatide as an antidiabetes ... per group (**GLP-1 receptor agonist**, **DPP-4 inhibitor**, or control **medication**). the **FDA Adverse Event Reporting System**, helped with **analyses**, and **reviewed** the....

Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

www.ncbi.nlm.nih.gov/pmc/articles/PMC4110853/

Hypoglycemic **risk** was similar to placebo when a **DPP-4 inhibitor** was **used** as ... **drug-related adverse events**, including hypersensitivity reactions [Lo Re et al. ... **Pancreas-related adverse events** reported after authorization of DPP-4 of **GLP-1 receptor agonists** and **DPP-4 inhibitors: meta-analysis and systematic review**.

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors ...

www.hindawi.com/journals/jnme/2012/381713/

21 Sep 2012 ... Pharmacology of **GLP-1 Receptor Agonists** . **DPP-4 Inhibitors** ... through **systematic reviews** and **meta-analyses** of incretin studies as very ... Both **drugs** were tolerated well by subjects and resulted in similar weight insulin therapy comes with significant **risks** of **adverse events** such as hypoglycaemia.

Incretin treatment and risk of pancreatitis in patients with type 2 ...



Risk of pancreatic adverse events associated with the use of glucagon-like p



网页 新闻 图片 视频 更多 搜索工具

找到约 18,500 条结果 (用时 0.90 秒)

Safety of dipeptidyl peptidase 4 inhibitors: a perspective ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) 翻译此页

作者: T Karagiannis - 2014 - 被引用次数: 23 - 相关文章

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral ... Keywords: adverse effects, drug safety, dipeptidyl peptidase 4 inhibitors, pancreatitis, type 2 ... metformin or a GLP-1 agonist than a DPP-4 inhibitor [Karagiannis et al. receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

Incretin treatment and risk of pancreatitis in patients with ...

www.bmj.com/content/348/bmj.g2366 翻译此页

作者: L Li - 2014 - 被引用次数: 67 - 相关文章

2014年4月15日 - Ling Li, research associate12.; Jiantong Shen, lecturer3, ... Design Systematic review and meta-analysis. ... receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors in ... Evidence from randomised controlled trials has shown that GLP-1 Fig 2 Risk of pancreatitis events between patients with type 2 ...

Do GLP-1-Based Therapies Increase Cancer Risk?

care.diabetesjournals.org/content/36/Supplement_2/S245.full 翻译此页

作者: MA Nauck - 2013 - 被引用次数: 32 - 相关文章

For the purpose of this review, GLP-1-based therapies are GLP-1 receptor agonists ... and others or dipeptidyl peptidase 4 (DPP-4) inhibitors such as sitagliptin. ... 30 cases of

[网页](#)[新闻](#)[图片](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 16,900 条结果 (用时 0.86 秒)

Safety of dipeptidyl peptidase 4 inhibitors: a perspective ...

www.ncbi.nlm.nih.gov > ... > [PubMed Central \(PMC\)](#) ▾ [翻译此页](#)

作者: T Karagiannis - 2014 - 被引用次数: 25 - [相关文章](#)

Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral ... Keywords: **adverse effects, drug safety, dipeptidyl peptidase 4 inhibitors, pancreatitis, type 2 ... metformin or a GLP-1 agonist** than a DPP-4 inhibitor [Karagiannis et al. **receptor agonists** and DPP-4 inhibitors: **meta-analysis and systematic review.**

Incretin treatment and risk of pancreatitis in patients with ...

www.ncbi.nlm.nih.gov/pubmed/24736555 ▾ [翻译此页](#)

作者: L Li - 2014 - 被引用次数: 71 - [相关文章](#)

2014年4月15日 - OBJECTIVE: To investigate the **risk of pancreatitis associated with the use of ... DESIGN: Systematic review and meta-analysis. ... peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase-4 (DPP-4) inhibitors** in adults ... A modified Cochrane tool **for randomised controlled trials** and a modified version of ...

Glucagon-like peptide-1 receptor agonists for the treatment ...

www.uptodate.com/.../glucagon-like-peptide-1-receptor-agonis... ▾ [翻译此页](#)

2015年9月9日 - (See "**Dipeptidyl peptidase 4 (DPP-4) inhibitors** for the treatment of type 2 ... with **GLP-1** and its **receptor agonists** is **associated** with weight loss, even ... on weight loss: **systematic review and meta-analyses of randomised controlled trials. ... Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.**

Do GLP-1–Based Therapies Increase Cancer Risk?

care.diabetesjournals.org/content/36/Supplement_2/S245.full ▾ [翻译此页](#)

作者: MA Nauck - 2013 - 被引用次数: 37 - [相关文章](#)

For the purpose of this **review, GLP-1–based therapies are GLP-1 receptor agonists**